Primary and secondary treatment for Helicobacter pylori in the United States

One of every 4 to 5 patients who receives antimicrobial therapy for Helicobacter pylori will not have successful eradication. Antimicrobial resistance, poor compliance with the antibiotic regimen, and drug-related side effects all play a role in determining the outcome of therapy. This article discusses the issues involved in H. pylori eradication, the mechanism of antibiotic delivery to the mucus layer of the stomach, and primary and secondary treatment strategies for H. pylori in the United States.     

Treatment of Helicobacter pylori Infection in Clinical Practice in the United States

Our objectives were to define treatment success, compliance, and side effects for treatment of Helicobacter pylori in clinical practice. In all, 224 consecutive patients received Helicobacter pylori treatment: 97 received two weeks of bismuth subsalicylate, metronidazole, tetracycline four times a day with a H₂-receptor antagonist twice a day (BMT); 89 received one week of metronidazole, lansoprazole, and clarithromycin twice a day (MLC); and 38 received one week of BMT with lansoprazole twice a day (BMT-PPI). Cure rates were: BMT 81% (95% CI 74–89%), MLC 90% (95% CI 84–96%) BMT-PPI 87% (95% CI 81–92%). More patients prescribed a bismuth-based regimen discontinued medications due to side effects compared to MLC (P = 0.049). Nausea was more common for BMT compared to MLC (P = 0.04). In conclusion, treatment of Helicobacter pylori infection with a one-week course of MLC achieves a high rate of cure in clinical practice. Significantly fewer patients prescribed PPI-based therapy discontinue medications due to side effects as compared to bismuth-based triple therapy.     

Helicobacter pylori seroprevalence in patients with lung cancer

AIM: To assess Helicobacter pylori(H pylori) seroprevalence in a cohort of Greek patients with lung cancer. METHODS: Seventy-two lung cancer patients (55 males and 17 females, aged 58.2±11.7 years) and 68, age and gender-matched, control subjects were enrolled. All subjects underwent an enzyme-linked immunosorbent assay IgG serologic test for H pylori diagnosis. RESULTS: A correlation between age and H pylori IgG level was detected for both lung cancer patients (r=0.42, P=0.004) and controls (r=0.44, P=0.004). Seropositivity for H pylori did not differ significantly between patients with lung cancer and controls (61.1% vs 55.9%, P>0.05). Concerning the mean serum concentration of IgG antibodies against H pylor,no significant difference between the two groups was detected (32.6±19.1 vs 27.4±18.3 U/mL,P>0.05). CONCLUSION: No significant association between H pylori infection and lung cancer was found.     

Helicobacter pylori seroprevalence in patients with chronic bronchitis

Background: Background: A high Helicobacter pylori seroprevalence has been found in many extragastrointestinal disorders. Moreover, it has been reported that the risk of chronic bronchitis may be increased in H. pylori-infected patients. The aim of this study was to assess the H. pylori seroprevalence in patients with chronic bronchitis. Methods: We evaluated 144 patients with chronic bronchitis (81 men and 63 women, aged 53.2 ± 12.7 years) and 120 age and sex-matched control subjects. All enrolled subjects (bronchitic patients and controls) underwent an enzyme-linked immunosorbent assay (ELISA) IgG serologic test for H. pylori diagnosis. Results: A correlation between age and H. pylori IgG level was detected for both bronchitic patients (r = 0.42; P= 0.004) and controls (r= 0.44; P= 0.004). H. pylori seroposivity in the chronic bronchitis group was significantly higher than that in controls (83.3% vs 60%; P= 0.007). The mean serum concentration of IgG antibodies against H. pylori was also significantly higher in patients with chronic bronchitis than in the control subjects (38.7 ± 24.1 U/ml vs 25.9 ± 19.3 U/ml; P = 0.02). Conclusions: Helicobacter pylori infection may be associated with chronic bronchitis. Further studies should be undertaken to confirm our results and to clarify the potential underlying pathogenetic mechanisms. Received: May 11, 2001 / Accepted: September 28, 2001     

Helicobacter pylori seroprevalence in patients with chronic bronchitis

AIM: A high rate of seropositivity for antibodies against Helicobacter pylori has been found in many extra-gastrointestinal diseases. In addition, it has been reported that the risk of chronic bronchitis may be increased in subjects infected with H. pylori. This study was designed to determine the H. pylori seroprevalence in patients with and without chronic bronchitis. MATERIALS AND METHODS: This study enrolled 68 patients with chronic bronchitis (40 men and 28 women, aged 50.5+/-16.2 years (mean+/-standard deviation) and 95 control subjects (60 men and 35 women, aged 51.8+/-15.9 years) matched for age and sex. An enzyme-linked immunosorbent assay immunoglobulin (Ig) G test for H. pylori diagnosis was performed on all enrolled subjects (those with chronic bronchitis and controls). RESULTS: Forty-five of 68 patients with chronic bronchitis (66.1%) and 48 of 95 subjects in the control group (57.7%) tested positive for H. pylori (P=0.008). Rates of H. pylori infection are higher in patients with chronic bronchitis than in the control group. CONCLUSION: The main conclusion of this study is that H. pylori infection is associated with an increased prevalence chronic bronchitis. Further studies should be planned to understand the potential pathogenetic mechanisms that might underlie this association.     

Helicobacter pylori seroprevalence in Amerindians from isolated locations

Helicobacter pylori seems universally distributed in all human populations, with high prevalence in the third world. Because H. pylori is an ancestral indigenous microbe of the human stomach, we hypothesized that its prevalence in isolated Amerindians would be high. A serologic study was performed on 19 Guahibo-Piaroa and 17 Warao in Venezuela, using H. pylori whole cell (WC) and CagA antigens from US strains. For Guahibo-Piaroa Amerindians, CagA seropositivity was 95%, but WC seropositivity was only 74%. For Warao, both CagA and WC seropositive proportions were low (65% and 76%, respectively). Because all CagA-seropositive individuals carry H. pylori, the results suggest that there has been bacterial antigen divergence, probably caused by genetic drift/natural selection, on humans and their microbes in isolated human groups.     

Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States

The seroprevalence of Helicobacter pylori infection was examined in the adult US population and among different ethnic groups. Stored sera from 7465 adult participants in the first phase of the third National Health and Nutritional Examination Survey (1988-1991) were tested with a sensitive and specific IgG ELISA, to diagnose infection. Seroprevalence of H. pylori among all participants was 32. 5%. This increased with age, from 16.7% for persons 20-29 years old to 56.9% for those > or =70 years old. Age-adjusted prevalence was substantially higher among non-Hispanic blacks (52.7%) and Mexican Americans (61.6%) than among non-Hispanic whites (26.2%). After controlling for age and other associated factors, the odds ratios relative to non-Hispanic whites decreased for non-Hispanic blacks, from 3.9 (95% confidence interval [CI], 3.1-4.9) to 3.3 (95% CI, 2. 6-4.2), and for Mexican Americans, from 6.3 (95% CI, 4.8-8.3) to 2.3 (95% CI, 1.6-3.5). The high prevalence of H. pylori infection among non-Hispanic blacks and Mexican Americans is partially explained by other factors associated with infection.     

Helicobacter pylori seroprevalence in patients with chronic obstructive pulmonary disease

An increased seroprevalence of Helicobacter pylori (H. pylori) and especially of the high virulent cytotoxin-associated gene-A (CagA) positive strains has been found in several extragastroduodenal pathologies, characterized by activation of inflammatory mediators. Moreover, it has been reported that the risk of chronic bronchitis may be increased in H. pylori infected patients. The aim of the present study was to assess the seroprevalence of H. pylori and in particular of CagA-positive virulent strains in patients with chronic obstructive pulmonary disease (COPD). We evaluated 126 COPD patients (88 males and 38 females, aged 61.3+/-8.1 years) and 126, age and sex-matched, control subjects. All subjects enrolled underwent an enzyme-linked immunosorbent assay (ELISA) IgG serologic test for H. pylori and CagA protein. The prevalence of H. pylori infection in patients and controls was 77.8% and 54.7%, respectively (P<0.001) and that of CagA-positive H. pylori infection was 53.9% and 29.3%, respectively (P<0.001). Moreover, COPD patients had a significantly increased mean serum concentration of both anti-H. pylori IgG (118.3+/-24.4 vs. 61.9+/-12.9U/ml, P<0.001) and anti-CagA IgG antibodies (33.8+/-3.4 vs. 19.0+/-1.5U/ml, P<0.001). Finally, no statistically significant difference, as regards the spirometric values, was detected between H. pylori infected COPD patients and uninfected ones. In conclusion, H. pylori infection may be associated with COPD. Further studies should be undertaken to clarify the potential underlying pathogenetic mechanisms.     

Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States

BACKGROUND: Therapy for Helicobacter pylori is generally empiric despite the fact that resistance to metronidazole and clarithromycin compromise therapeutic efficacy. The aim of this study was to aid clinicians in choosing a course of therapy for H pylori infection in the United States. METHODS: The frequency of primary clarithromycin and metronidazole resistance among H pylori isolated from patients enrolled in US-based clinical trials between 1993 and 1999 was reviewed in relation to patient age, sex, region of the United States, and test method (Etest and 2 agar dilution procedures). RESULTS: Clarithromycin and metronidazole resistance rates were based on the results of 3439 pretreatment Etest determinations and 3193 agar dilution determinations. Sex and age were available on 900 and 823 individuals, respectively. Metronidazole resistance was 39% by Etest and 21.6% by agar dilution (P<.001). Clarithromycin resistance was 12% by Etest and 10.6% by agar dilution. Amoxicillin or tetracycline resistance was rare. Metronidazole and clarithromycin resistance was more common in women than men (eg, 34.7% vs 22.6% for metronidazole and 14.1% vs 9.7% for clarithromycin (P =.01 and P =.06, respectively). Antibiotic resistance increased gradually up to age 70 years, then declined significantly (P<.05) regardless of test method. Regional differences in antimicrobial resistance did not occur. CONCLUSIONS: While age and sex had significant effects on resistance rates, regional differences were not present. The high prevalence of resistance to metronidazole and clarithromycin may soon require the performance of antimicrobial susceptibility testing of H pylori isolates prior to initiating treatment.     

Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status

A causative role is now accepted for Helicobacter (formerly Campylobacter) pylori in type B gastritis, and evidence is accumulating that H. pylori infection plays a major contributory role in peptic ulcer disease. Preliminary studies have reported that the prevalence of H. pylori infection increases with age, but detailed information on the prevalence of the bacteria in any defined population and on the factors that may influence the pattern of distribution remains scanty. In the present study, a sensitive enzyme-linked immunosorbent assay and a [13C] urea breath test were used to investigate the prevalence of H. pylori infection among 485 healthy asymptomatic volunteers between the ages of 15 and 80 residing in the Houston metropolitan area. H. pylori infection was present in 52%. The prevalence of H. pylori infection increased rapidly with age at 1%/yr for the overall population. The frequency of H. pylori infection was higher in blacks (70%) than whites (34%) (P less than 0.001); this difference remained after adjustments were made for age, gender, educational level, income, and use of tobacco or alcohol. H. pylori infection was independent of gender but was closely correlated with socioeconomic class. There were significant inverse correlations between age-adjusted frequency of H. pylori infection and income and between educational level and H. pylori infection. There was no association between H. pylori infection and consumption of alcohol or nonsteroidal antiinflammatory drug use or smoking. Having pets was associated with a lower frequency of H. pylori infection, but this was highly associated with higher socioeconomic status. The mode(s) of transmission of H. pylori is unknown, but the social patterns of H. pylori infection are consistent with fecal-oral transmission as one important pathway. Socioeconomic factors seem to determine the age of acquisition.     

Management of Helicobacter pylori Infection: A Comparison between Korea and the United States

Helicobacter pylori has been well known to cause gastritis, peptic ulcers, mucosa-associated lymphoid tissue, and gastric cancer. The importance of H. pylori eradication has been emphasized; however, the management of H. pylori infection is difficult in clinical practice. In both Eastern and Western countries, there has been a constant interest in confirming individuals who should be tested and treated for H. pylori infection and developing methods to diagnose H. pylori infection. Many studies have been implemented to successfully eradicate H. pylori, and various combinations of eradication regimens for H. pylori infection have been suggested worldwide. Based on the findings of previous studies, a few countries have published their own guidelines that are appropriate for their country; however, these country-specific guidelines may differ depending on the circumstances in each country. Evidence-based guidelines and clinical practice updates for the treatment of H. pylori infection have been published in Korea and the United States in 2021. This review will summarize the similarities and differences in the management of H. pylori infection in Korea and the United States, focusing on indications, diagnosis, and treatments based on recent guidelines and recommendations in both countries.     

Helicobacter pylori eradication in the Swedish population

Objectives: Helicobacter pylori is associated with peptic ulcers and gastric cancer and its eradication aims to prevent these conditions. The recommended eradication regimen is triple therapy, consisting of a proton-pump inhibitor in combination with clarithromycin and amoxicillin or metronidazole for 7 days. Yet, other antibiotic regimens are sometimes prescribed. We aimed to assess the use of eradication therapy for H. pylori in the Swedish population during the last decade.

Materials and methods: This population-based study used data from the Swedish Prescribed Drug Register. From July 2005 until December 2014, all regimens that can eradicate H. pylori were identified and evaluated according to patients’ age and sex and calendar year of eradication.

Results: We identified 157,915 eradication episodes in 140,391 individuals (53.8% women, 42.6% older than 60 years), who correspond to 1.5% of the Swedish population. The absolute number and incidence of eradications decreased over the study period. Overall, 91.0% had one eradication and 0.1% had more than three. Of all eradications, 95.4% followed the recommended regimen, while 4.7% did not. The latter group was overrepresented among individuals aged ≥80 years (7.8%). Amoxicillin and clarithromycin were most frequently prescribed, while metronidazole was rarely used (0.01%). Other prescribed antibiotics were ciprofloxacin (2.4%), doxycycline (1.4%), nitrofurantoin (0.7%), norfloxacin (0.5%) and erythromycin (0.3%).

Conclusions: During the last decade in Sweden H. pylori eradication has been frequently prescribed, but the incidence of eradication has slowly declined. Most eradications followed the recommended regimen, including those occurring after a previous eradication.